
XORTX Therapeutics Secures Orphan Drug Designation for Oxypurinol to Treat Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company that aims to create new therapies to treat progressive kidney disease, is excited to announce that they have received Orphan Drug ...